H.C. Wainwright raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $96.00 (from $90.00) while maintaining a Buy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular DystrophyMay 7, 2018 7:30 AM Sarepta Therapeutics (SRPT) PT Raised to $109 at Needham & CompanyMay 7, 2018 6:20 AM Pre-Open Stock Movers 05/04: (PTLA) (CVGI) (SHAK) Higher; (IMTE) (FLR) (ANET) Lower (more...)May 4, 2018 9:09 AM Sarepta Therapeutics (SRPT) PT Raised to $98 at RBC CapitalMay 4, 2018 8:50 AM Sarepta Therapeutics (SRPT) PT Lowered to $90 at H.C. WainwrightMay 4, 2018 7:14 AM Sarepta Therapeutics' (SRPT) In Line Quarter Shifts Focus To R&D DayMay 4, 2018 7:01 AM Sarepta Therapeutics (SRPT) PT Raised to $91 at Morgan StanleyMay 4, 2018 6:44 AM Sarepta Therapeutics (SRPT): R&D Day Should Reveal Gene Therapy Data - BairdMay 4, 2018 6:43 AM Oppenheimer Downgrades Sarepta Therapeutics (SRPT) to PerformMay 4, 2018 5:31 AM Sarepta Therapeutics (SRPT) PT Lowered to $90 at JMP SecuritiesMay 4, 2018 4:08 AM Oppenheimer Downgrades Sarepta Therapeutics (SRPT) to PerformMay 4, 2018 2:37 AM After-Hours Stock Movers 05/03: (CVGI) (VIAV) (SHAK) Higher; (FLR) (ANET) (TSRO) Lower (more...)May 3, 2018 6:01 PM Sarepta Therapeutics (SRPT) Tops Q1 EPS by 4cMay 3, 2018 4:05 PM Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular DystrophiesMay 3, 2018 4:01 PM Sarepta Therapeutics Announces First Quarter 2018 Financial Results and Recent Corporate DevelopmentsMay 3, 2018 4:01 PM